• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Novel preemptive intervention effective in reducing autism spectrum disorder severity and rate of diagnosis

byBipandeep AbbatandAlex Chan
October 6, 2021
in Chronic Disease, Neurology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a randomized-controlled trial amongst infants showing early signs of autism spectrum disorder a preemptive intervention, used when atypical development first emerges, reduced the severity of symptoms and rates of diagnosis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although children with autism spectrum disorder (ASD) demonstrate symptoms in earlier development, therapeutic interventions are not begun till diagnosis. There have been recent advancements in developmental sciences that demonstrate the effect of caregiver interaction styles on infant development. Specifically, a newer intervention, the iBASIS-Video Interaction to Promote Positive Parenting (iBASIS-VIPP), is evaluating this concept. It utilized video feedback to increase caregiver awareness of their infant’s social communication skills and guide specific caregiver responses to build infant social engagement. According to emerging theories, such interventions beginning when the earliest signs of atypical development are observed and the brain is still developing, may result in a larger impact of outcomes in later childhood. However, there has been no research demonstrating effects of preemptive interventions on ASD symptom emergence.

This is a single-rater blinded randomized clinical trial conducted at 2 different research centers. 104 participants between 9 to 15 months were included. They all displayed at least 3 of 5 specified behaviours indicating high likelihood of ASD as per the Social Attention and Communication Surveillance-Revised (SACS-R) 12-month checklist. They were then divided in a 1:1 ratio to receive either the iBASIS-VIPP intervention plus usual community care or usual community care only. The intervention involved 10 sessions delivered to families by a therapist where the video-taped interaction between the caregiver and infant dyad would be reviewed and discussed. Based on this, caregivers were asked to complete daily home practice using targeted skills when interacting with the infant. The control group received usual care recommended by community practitioners. Infants were assessed at baseline, treatment end point, age 2 years, and age 3 years. The primary outcome measured by ASD severity over time, assessed by the Autism Observation Scale for Infants (AOSI). The study demonstrated that there is reduced ASD symptom severity in the intervention group from treatment endpoint to 12-month postbaseline assessment. The secondary outcomes measured were clinical ASD diagnosis at age 3 years and measures of child development. It was found that there were reduced odds of ASD diagnosis in the iBASIS-VIPP group compared to control.

This was one of the first randomized controlled trial to evaluate preemptive intervention for infants showing early signs of ASD. It did so to evaluate new developmental theories, thus filling a gap in the literature. Additionally, it was well designed to improve internal validity of the experiment. For instance, randomization of infants was performed after stratifying the infants by site, sex, numner of behaviours indicating a higher likelihood of ASD on the SACS-R (endorsement of 3, 4, or 5 behaviours) and age range at recruitment (9-11 months or 12-14 months). The research staff conducting assessments were independent of team administrating intervention and they were blinded of group allocation. There was also high participant retention across the 4 assessment points spanning 2 years. One of the limitations of this study is the smaller sample, especially since prior similar studies demonstrated mixed results. Additionally, infants were only followed till the 3-year point, and although rare, their diagnostic classification could change if reassessed at later times. Therefore, future larger-scale studies are required to confirm the results found in this study. Future studies can focus on evaluating other preemptive interventions and comparing their effects on ASD symptom severity and diagnosis.

Click to read the study in JAMA Pediatrics  

Relevant Reading: Early detection for better outcomes: universal developmental surveillance for autism across health and early childhood education settings.

RELATED REPORTS

2 Minute Medicine Rewind June 13, 2022 

2 Minute Medicine Rewind June 6, 2022

2 Minute Medicine Rewind May 22nd, 2022

In-Depth [randomized controlled trial]: A total of 89 participants were assessed at the end of the study, 45 in the intervention group and 44 in the control group. Both groups had similar baseline characteristics (mean [SD] age, 12.40 [1.93] months vs 12.38 [2.02] months, respectively; 76.0% male vs 60.4% male). The study found that there was reduced ASD symptom severity in the intervention group from treatment end point to the 12-month postbaseline assessment which was maintained at the 24-month postbaseline assessment. The combined treatment effect was statistically significant with an area between curves of -5.53 (95% CI,  −∞ to −0.28; P = 0.04). It also showed reduced odds of ASD diagnostic classification at age 3 in the intervention group compared to the control group (3 out of 45 participants [6.7%] versus 9 out of 44 participants [20.5%]; odds ratio, 0.18; 95% CI, 0-0.68; P = 0.02).

Image PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: autismdevelopmental pediatricsneurologypediatrics
Previous Post

Men may be 2.5 times more likely to die from COVID-19 than women

Next Post

Use of menopausal hormone therapy and risk of dementia

RelatedReports

Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind June 13, 2022 

June 20, 2022
Weekly Rewinds

2 Minute Medicine Rewind June 6, 2022

June 6, 2022
Weekly Rewinds

2 Minute Medicine Rewind May 22nd, 2022

May 23, 2022
Isolated mild/moderate thrombocytopenia may not require intervention
Pediatrics

Ambient air pollution associated with increased risk of Kawasaki disease in children

May 9, 2022
Next Post
Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine

Use of menopausal hormone therapy and risk of dementia

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Evaluation of epidural analgesia use during labor and infection in full-term neonates delivered vaginally

Reduced gestational weight gain with lifestyle intervention

Structured aerobic exercise may produce less weight loss than expected

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.